2seventy bio, Inc. (TSVT)
- Previous Close
5.0000 - Open
5.0000 - Bid --
- Ask --
- Day's Range
5.0000 - 5.0000 - 52 Week Range
2.2900 - 5.3000 - Volume
1,158,184 - Avg. Volume
1,373,116 - Market Cap (intraday)
266.142M - Beta (5Y Monthly) 1.05
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0800 - Earnings Date Aug 5, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.00
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
www.2seventybio.comRecent News: TSVT
View MorePerformance Overview: TSVT
Trailing total returns as of 5/20/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TSVT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TSVT
View MoreValuation Measures
Market Cap
266.14M
Enterprise Value
335.53M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.43
Price/Book (mrq)
1.24
Enterprise Value/Revenue
6.94
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-8.46%
Return on Assets (ttm)
-7.49%
Return on Equity (ttm)
-1.94%
Revenue (ttm)
48.37M
Net Income Avi to Common (ttm)
-4.09M
Diluted EPS (ttm)
-0.0800
Balance Sheet and Cash Flow
Total Cash (mrq)
170.38M
Total Debt/Equity (mrq)
112.06%
Levered Free Cash Flow (ttm)
-40.38M